W

ASHINGTON — Seeking new ways to lower drug prices, White House advisers have raised the prospect of fast-tracking the review process for some brand-name medications submitted for approval to the Food and Drug Administration.

The FDA already prioritizes the review of drugs that are the first, second, and third generics of any given brand. The new idea, outlined in a report from the Council of Economic Advisers released Friday, might expand such a policy to brand-name drugs that treat similar diseases but can’t be interchanged like generics can be.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.